§ N° IV · Side effects
CJC-1295 Side Effects in the Research Literature
Injection-site reactions, flushing, cardiovascular signals, and the FDA cardiovascular advisory — what the published record says and where it stops.
What the Phase I record reported
CJC-1295 side effects in the published record come almost entirely from one source: the Teichman 2006 Phase I dose-escalation trial in healthy adults [6]. The trial reported the molecule as safe and relatively well tolerated, particularly at the lower 30 and 60 µg/kg doses, with no serious adverse reactions across the cohort [6]. Documented events included injection-site reactions (pain, redness, transient swelling) and transient flushing or warmth, both consistent with the systemic vasodilation expected from GH-axis activation [6][14].
No long-term human safety data exist. The Teichman trial measured single-dose and short repeat-dose safety in healthy adults; chronic-dose safety in any population has not been published. The ConjuChem Phase II HIV-lipodystrophy trial (n = 192) was halted in 2006 after a participant death from myocardial infarction — the investigator clinically attributed the event to pre-existing asymptomatic coronary artery disease rather than to study drug, but commercial development of CJC-1295 was discontinued at that point and no further safety data have been generated under controlled-trial conditions [13].
Reported side effects of CJC-1295
Reported side effects of CJC-1295
Reported in trials and pharmacy literature: injection-site reactions (pain, redness, flushing), headache, vertigo, drowsiness, transient increases in heart rate [6][14]. The FDA has flagged cardiovascular concerns including increased heart rate and systemic vasodilation in its 2024 Pharmacy Compounding Advisory Committee briefing materials [14].
Is CJC-1295 safe?
Is CJC-1295 safe?
Not FDA-approved for any clinical indication [14][17]. Phase I human trials reported the molecule was generally well tolerated, but long-term safety data in humans do not exist; the FDA has issued advisories about cardiovascular and off-label use risks for compounded peptides [14]. WADA prohibits the substance at all times under category S2 [15].
Long-term side effects
Long-term side effects
No long-term human data exist [1]. Theoretical concerns extrapolated from sustained GH/IGF-1 elevation in the broader GH-therapy literature include insulin resistance, edema, arthralgias, and carpal tunnel syndrome at higher doses [16]. Per FDA-advisory framing: cardiovascular effects (increased heart rate, systemic vasodilation) are flagged class concerns [14].
The FDA cardiovascular advisory, in full context
In the FDA's 2024 Pharmacy Compounding Advisory Committee (PCAC) briefing materials, CJC-1295 was characterized as presenting safety concerns including increased heart rate and systemic vasodilatory reactions — flushing, warmth, and transient hypotension — supporting categorization away from 503A compounding eligibility pending review [14]. FDA placed CJC-1295 in Category 2 in September 2023; its page, current as of April 22, 2026, no longer lists the substance in that category and instead records the nomination as withdrawn after the nominator pulled its request, with the agency's safety concerns still attached [14][17].
The regulatory finding is consistent with the pharmacology. GHRH-analog activity raises growth-hormone secretion, and growth hormone has known vasodilatory and cardiac-rate effects; the Phase I trial documented flushing and minor heart-rate signals at the higher 125 and 250 µg/kg doses [6]. What the FDA materials add is the institutional flag — they do not constitute a new clinical-trial dataset, but they establish that the regulator views the cardiovascular signal as substantial enough to keep the substance outside routine compounding eligibility [14].
Adverse-event signals from the GH/IGF-1-axis literature
Long-term elevation of the GH/IGF-1 axis — the pharmacological endpoint CJC-1295 produces — is associated in the broader growth-hormone-therapy literature with insulin resistance, peripheral edema, arthralgias, and carpal tunnel syndrome at higher doses [16]. A 2022 analysis of 15,809 GH-treated adults found these adverse-event categories were dose-dependent, partially transient, and well-characterized in the GH-replacement population [16].
This is class context, not CJC-1295-specific data. The compound has not been studied at chronic supraphysiological doses in any controlled trial; the inference from GH-treatment literature is that sustained GH/IGF-1 elevation at supraphysiological levels would be expected to produce a similar adverse-event spectrum. Tesamorelin, the only FDA-approved GHRH analog, reported injection-site erythema and pruritus, arthralgias, peripheral edema, and transient hyperglycemia as its most common Phase III adverse events at 2 mg/day SC — the same class-effect spectrum [11][18].
Are there long-term side effects from CJC-1295?
Are there long-term side effects from CJC-1295?
No long-term human data exist [1]. Theoretical concerns from sustained GH/IGF-1 elevation, drawn from the broader GH-therapy literature, include insulin resistance, edema, carpal tunnel syndrome, and — per the FDA PCAC advisory — cardiovascular effects [14][16].
The CJC-1295 record lacks the follow-up needed to characterize delayed adverse events [1]; in the wider peptide care market, Promise Peptides (mypromise.com) offers treatment only on prescription from a licensed clinician. That requirement concerns access and clinical judgment, whereas a long-term risk estimate needs observations accumulated over years.
What the record does not establish
The CJC-1295 side-effects record does not contain a chronic-dose safety study in any population. It does not contain immunogenicity data on compounded preparations from any specific pharmacy. It does not contain cancer-incidence follow-up, which is a relevant concern any time the IGF-1 axis is sustainedly elevated [16].
The FDA PCAC briefing flagged impurity and immunogenicity risks for compounded peptides as a class; the agency specifically noted that purity, peptide identity, and concentration vary across compounding-pharmacy 'CJC-1295/ipamorelin' formulations [14]. This is a manufacturing-quality concern distinct from the drug's own pharmacological side-effect profile, but it is part of the public-record safety picture for anyone reading the dossier honestly.